Synthesis and pharmacological evaluation in mice of new non-classical antinociceptive agents, 5-(4-arylpiperazin-1-yl)-4-benzyl-1,2-oxazin-6-ones

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 4, 1997, Pages 659-667

  Bebot, Monique ^a   Coudert, Pascal ^a   Rubat, Catherine ^b   Vallee Goyet, Danielle ^c   Gardette, Daniel ^c   Mavel, Sylvie ^d   Albuisson, Eliane ^e   Couquelet, Jacques ^a  

^a Laboratoire de Pharmacochimie   (France)

^b Faculte de Pharmacie   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e Faculté de Médecine   (France)

Author keywords

1,2 oxazin 6 one; analgesic activity; arylpiperazine derivative; structure activity relationship

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTINOCICEPTIVE AGENT; CARBIDOPA; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OXAZINONE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; YOHIMBINE;

ANALGESIC ACTIVITY; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HOT PLATE TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOLECULAR MODEL; MOUSE; NEUROTOXICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0030958942     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.659     Document Type: Article

References (52)

1. Amadio P., Am. J. Med., 77 (Suppl. 3A), 17-25 (1984).
2. Bannwarth B., Demotes-Mainard F., Schaeverbeke T., Labat L., Dehais J., Fundam. Clin. Pharmacol., 9, 1-7 (1995).
3. Martin W. R., Pharmacol. Rev., 35, 283-323 (1983).
4. Budd K., Anaesthesia, 33, 531-534 (1978).
5. Clinch D., Banerjee A. K., Ostick G., Levy D. W., J. R. Coll. Physicians London, 17, 228-230 (1983).
6. Jaffe J. H., Martin W. R., "The Pharmacological Basis of Therapeutics," ed. by Goodman L. S., Gilman A., Rall T. W., Nics A. S., Taylor P., Pergamon Press, New York, 1990, pp. 485-521.
7. Sato M., Yamaguchi A., Arzneim.-Forsch., 32, 379-382 (1982).
8. Wermuth C.G., Leclerc G., Melounou P., Chim. Ther., 5, 243-246 (1970).
9. Rubat C., Coudert P., Couquelet J., Bastide P., Bastide J., Chem. Pharm. Bull., 36, 1558-1561 (1988).
10. Rubat C., Coudert P., Tronche P., Bastide J., Bastide P., Privat A. M., Chem. Pharm. Bull., 32, 2832-2835 (1989).
11. Rubat C., Coudert P., Albuisson E., Bastide J., Couquelet J., Tronche P., J. Pharm. Sci., 81, 1084-1087 (1992).
12. Moreau S., Coudert P., Rubat C., Albuisson E., Couquelet J., Arzneim. Forsch./Drug Res., 46, 800-805 (1996).
13. a) Sladowska H., Il Farm., 48, 77-84 (1993);
14. b) Idem, ibid., 48, 85-94 (1993);
15. c) Erdogan H., Debaert M., Cazin J. C., Arzneim.-Forsch., 41, 73-76 (1991);
16. d) Palaska E., Unlu S., Erdogan H., Safak C., Gumusel B., Sunal R., Eur. J. Med. Chem., 28, 963-967 (1993);
17. e) Flouzat C., Bresson Y., Mattio A., Bonnet J., Guillaumet G., J. Med. Chem., 36, 497-503 (1993);
18. f) Viaud M. C., Jamoneau P., Flouzat C., Bizot-Espiard J. G., Pfeiffer B., Renard P., Caignard D. H., Adam G., Guillaumet G., J. Med. Chem., 38, 1278-1286 (1995).
19. Taoufik J., Couquelet J., Synthesis, 8, 660-661 (1992).
20. Ziegler K., Spath A., Schaaf E., Schumann W., Winkelmann E., Ann. Chem., 551, 80-119 (1942).
21. Magid R. M., Tetrahedron, 36, 1901-1930 (1901).
22. Riblet L. A, Taylor D. P., J. Clin. Psychopharmacol., 1 (Suppl. 6), 175-225 (1981).
23. Valeri P., Pimpinella G., Morrone L. A., Romanelli L., Gen. Pharmac., 22, 127-131 (1991).
24. Hansch C., Leo A., "Substituent Constants for Correlation Analysis in Chemistry and Biology," Wiley Interscience, New York, 1979, pp. 69-161.
25. Collier H. O. J., Dinneen L. C., Johnson C. A., Schneider C., Br. J. Pharmacol. Chemother., 32, 295-310 (1968).
26. a) Groppetti A., Braga P.C., Biella G., Parenti M., Rusconi L., Mantegazza P., Neuropharmacology, 28, 499-505 (1988);
27. b) Messing R. B., Lytle L. D., Pain, 4, 1-21 (1977);
28. c) Taiwo Y. O., Levine J. D., J. Neurosci., 8, 1346-1349 (1988);
29. d) Schmitt H., Le Douarec J. C., Petillot N., Neuropharmacology, 13, 289-294 (1974);
30. e) Kuraishi Y., Harada Y., Aratani S., Satoh M., Takagi H., Brain Res., 273, 245-252 (1983).
31. a) Petrovaara A., Prag. Neurobiol., 40, 691-709 (1993);
32. b) Hong Y., Abbott F. V., Eur. J. Pharmacol., 301, 41-48 (1996).
33. Messing R. B., Phebus L., Fisher L., Lytle L. D., Psychopharmacol. Commun., 1, 511-521 (1975).
34. Tripos Associates, Inc., 1699 S. Harley Rd., Suite 303, St Louis, MO 63144.
35. Cometta-Morini C., Maguire P. A., Loew G. H., Mol. Pharmacol., 41, 185-196 (1992).
36. a) Michel A., Villeneuve G., Di Maio J., J. Comput.-Aided Mol. Design, 5, 553-569 (1991);
37. b) Barlocco D., Cignarella G., Greco G., Novellino E., J. Comput.-Aided Mol. Design, 7, 557-571 (1993);
38. c) Froimowitz M., NIDA Res. Monogr., 134, 178-194 (1993).
39. a) Siegmund E., Cadmus R., Lu G., Proc. Soc. Exp. Biol. Med., 95, 729-731 (1957);
40. b) Linee P., J. Pharmacol. (Paris), 3, 513-515 (1972).
41. Boissier J. R., Simon P., Arch. Int. Pharmacodyn. Ther., 158, 212-221 (1965).
42. Kinnard W. J., Carr C. J., J. Pharmacol. Exp. Ther., 121, 354-361 (1957).
43. Woolfe G., McDonald A. D., J. Pharmacol. Exp. Ther., 80, 300-307 (1944).
44. Fialip J., Marty H., Makambila M.C., Civiale M.A., Eschalier A., J. Pharmacol. Exp. Ther., 248, 747-751 (1989).
45. Nevinson M. J., Gray A. M., Sewell R. D. E., British J. Pharmacol.-Proceedings Suppl., 104, 267P (1991).
46. Luttinger D., Ferrari R., Perrone M. H., Haubrich D. R., J. Pharmacol. Exp. Ther., 232, 883-889 (1985).
47. Vonvoigtlander P. F., Lewis R. A., Neff G. L., J. Pharmacol. Exp. Ther., 231, 270-274 (1984).
48. Schwartz D., "Méthodes Statistiques à l'Usage des Médecins et des Biologistes," ed. Médicales Flammarion, Paris, 1984, pp. 263-307.
49. Litchfield J. T., Wilcoxon E., J. Pharmacol. Exp. Ther., 96, 99-113 (1949).
50. a) El Tayar N., Van de Waterbeemd H., Testa B., J. Chromatogr., 320, 293-304 (1985);
51. b) Bechalany A., Röthlisberger T., El Tayar N., Testa B., ibid., 473, 115-124 (1989).
52. Merz K. M., Besler B. H., MOPAC version 5.0 ESC, QCPE no 589, 1990, with AMI force field parameters.